Robert W. Baird started coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a report released on Monday. The brokerage issued an outperform rating and a $3.00 target price on the biotechnology company’s stock.
A number of other equities analysts have also recently weighed in on the stock. Piper Jaffray Companies reaffirmed an overweight rating and set a $5.00 price objective on shares of Genocea Biosciences in a research report on Thursday, November 2nd. Zacks Investment Research raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $1.75 price objective for the company in a research report on Monday, October 16th. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $3.00 price objective for the company in a research report on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $4.21.
Genocea Biosciences (NASDAQ GNCA) opened at $0.98 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51. Genocea Biosciences has a 1 year low of $0.79 and a 1 year high of $7.29.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.